Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kairos Pharma, LTD.

NYSE: KAPA · Life Sciences · 4 alerts · CIK 1962011

Share price
$0.4069Close, Nov 16
Market cap
$1.91M
Shares outstanding
4.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kairos Pharma, LTD. filings on SEC EDGAR ↗

5:08 PM ET 10-Q
Financial Results

Kairos Pharma Q3 2026 Results: Net Loss of $1.98M, Loss Widens

Kairos Pharma, Ltd. reported a net loss of $5.03 million for the nine months ended September 30, 2026, compared to a $4.08 million loss in the prior year period. The company remains in the development stage with no revenue, and its cash position decreased to $3.13 million as of September 30, 2026, from $4.49 million at year-end 2025.

Key figure
Net loss $1.98M
11:51 AM ET 8-K
Capital Raise

Kairos Pharma Capital Raise

Kairos Pharma, Ltd. entered into a third amendment to its existing equity line of credit (ELOC) purchase agreement with Helena Global Investment Opportunities I Ltd. The amendment extends the company's option to use the ELOC for an additional year until December 31, 2028, and follows previous amendments that adjusted the purchase price to 97% of VWAP and shortened the pricing period.

Counterparty
Helena Global Investment Opportunities I Ltd.
Term
through Dec 2028

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.